Evolution of the short-term TEER in Calu-3 cell monolayers during the monolayer maturation. by Aizat Turdalieva (2512252)

Temporal profiles of the key BO-NN features. by Julia Berezutskaya (9080269)

“…Right plot show the gradual decrease in the TM tuning for the features highlighted in <b>c</b> as well as the gradual increase in the temporal response profile (i.e. optimal shifts for the prediction of the key BO-NN features using Praat features shown in <b>a</b>). …”

Log2 fold changes in control and ATRX knockdown HFFs upon IFN-β stimulation. by Anne-Charlotte Stilp (3520415)

<i>S</i>. Typhimurium coordinates protein synthesis with protein folding capacity. by Carissa Chan (18310140)

Subjects:

Predicted <i>cis</i>-acting elements in <i>DpAP2</i> promoter. by Lingru Ruan (18995544)

“…Carotenoid biosynthesis was enhanced by <i>DpAP2</i> overexpression (1.4930 fold of control) and exogenous substances such as GA3 (1.5889 fold of control), which laid a foundation for massive accumulation of carotenoids in microalgae. …”

Genes displaying >two-fold differences in expression between metastasising and non-metastasising MCTs. by Kelly Bowlt Blacklock (6102878)

Synthesis and Antiproliferative Activity of a New Series of Mono- and Bis(dimethylpyrazolyl)‑<i>s</i>‑triazine Derivatives Targeting EGFR/PI3K/AKT/mTOR Signaling Cascades by Ihab Shawish (13015516)

“…The antiproliferative activity of the novel <i>mono</i>- and <i>bis</i>(dimethylpyrazolyl)-<i>s</i>-triazine derivatives was studied against three cancer cell lines, namely, MCF-7, HCT-116, and HepG2. <i>N</i>-(4-Bromophenyl)-4-(3,5-dimethyl-1<i>H</i>-pyrazol-1-yl)-6-morpholino-1,3,5-triazin-2-amine <b>4f</b>, <i>N</i>-(4-chlorophenyl)-4,6-bis­(3,5-dimethyl-1<i>H</i>-pyrazol-1-yl)-1,3,5-triazin-2-amine <b>5c</b>, and 4,6-<i>bis</i>(3,5-dimethyl-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-(4-methoxyphenyl)-1,3,5-triazin-2-amine <b>5d</b> showed promising activity against these cancer cells: <b>4f</b> [(IC₅₀ = 4.53 ± 0.30 μM (MCF-7); 0.50 ± 0.080 μM (HCT-116); and 3.01 ± 0.49 μM (HepG2)]; <b>5d</b> [(IC₅₀ = 3.66 ± 0.96 μM (HCT-116); and 5.42 ± 0.82 μM (HepG2)]; and <b>5c</b> [(IC₅₀ = 2.29 ± 0.92 μM (MCF-7)]. …”

Synthesis and Antiproliferative Activity of a New Series of Mono- and Bis(dimethylpyrazolyl)‑<i>s</i>‑triazine Derivatives Targeting EGFR/PI3K/AKT/mTOR Signaling Cascades by Ihab Shawish (13015516)

“…The antiproliferative activity of the novel <i>mono</i>- and <i>bis</i>(dimethylpyrazolyl)-<i>s</i>-triazine derivatives was studied against three cancer cell lines, namely, MCF-7, HCT-116, and HepG2. <i>N</i>-(4-Bromophenyl)-4-(3,5-dimethyl-1<i>H</i>-pyrazol-1-yl)-6-morpholino-1,3,5-triazin-2-amine <b>4f</b>, <i>N</i>-(4-chlorophenyl)-4,6-bis­(3,5-dimethyl-1<i>H</i>-pyrazol-1-yl)-1,3,5-triazin-2-amine <b>5c</b>, and 4,6-<i>bis</i>(3,5-dimethyl-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-(4-methoxyphenyl)-1,3,5-triazin-2-amine <b>5d</b> showed promising activity against these cancer cells: <b>4f</b> [(IC₅₀ = 4.53 ± 0.30 μM (MCF-7); 0.50 ± 0.080 μM (HCT-116); and 3.01 ± 0.49 μM (HepG2)]; <b>5d</b> [(IC₅₀ = 3.66 ± 0.96 μM (HCT-116); and 5.42 ± 0.82 μM (HepG2)]; and <b>5c</b> [(IC₅₀ = 2.29 ± 0.92 μM (MCF-7)]. …”

Enhancing Protein Crystal Nucleation Using In Situ Templating on Bioconjugate-Functionalized Nanoparticles and Machine Learning by Caroline McCue (14657922)

Effectiveness of E cytotoxicity presented as a half maximal growth inhibitory concentration (CC₅₀). by Anna Kalota (7415)

Multiple trauma and hemorrhagic shock induce a transcriptional immune response. by Marc-Alexander Oestreich (13961375)

Inhibition of G9a decreases the tumorigenicity of neuroblastoma cells. by Xiao-Xue Ke (626989)

Mutations in <i>DHFR-TS</i> and their role in methotrexate resistance. by Sophia Bigot (16469992)

Subjects:

Dominant positive effect of mutated versions of <i>PTR1</i>. by Sophia Bigot (16469992)

Subjects:

PTR1 DNA editing and absence of phenotype. by Sophia Bigot (16469992)

Subjects:

Inactivation of one allele of FT5. by Sophia Bigot (16469992)

Subjects:

<i>L</i>. <i>major</i> Friedlin <i>FT1</i> single knockout. by Sophia Bigot (16469992)

Subjects:

Selected mutations in the folate transporter <i>FT1</i> and their analysis by DNA editing. by Sophia Bigot (16469992)

Subjects:

Complete data. by Jan Víteček (11434774)

“…A tenfold decrease or increase in concentration induced only a 2-fold decrease or increase in clot degradation. …”

Fig 4 - by Jan Víteček (11434774)

“…A tenfold decrease or increase in concentration induced only a 2-fold decrease or increase in clot degradation. …”